
The publisher cited weak growth, operating losses and cash flow concerns in its assessment of Asana, Compass and Ocular Therapeutix.
StockStory flagged Asana, Compass and Ocular Therapeutix as unprofitable companies facing business challenges. It cited trailing 12-month GAAP operating margins of -19.4% for Asana, -2.6% for Compass and -603% for Ocular Therapeutix.
For Asana, StockStory pointed to average annual recurring revenue growth of 9.5% over the last year and a net revenue retention rate of 96.5%. The publisher also cited a drawn-out sales process with enterprise clients.
Compass's annual revenue growth averaged 14% over the last five years, which StockStory said fell short of its standards for the consumer discretionary sector. It also cited persistent operating losses and a lack of free cash flow.
For Ocular Therapeutix, StockStory noted that sales declined by 7.7% annually over the last two years. It also said earnings per share fell by 7.5% annually over the last five years, while revenue grew.
The publisher cited a 371.3 percentage point decline in Ocular Therapeutix's free cash flow margin over the last five years, which it linked to increased investment to defend the company's market position.
This article was produced with the help of AI technology. Source: Yahoo Finance